BACKGROUND: The aim of the study was to investigate safety, efficacy and tolerability of risperidone in comparison with haloperidol in the long-term treatment of autistic disorder. METHODS: This was an open-label continuation study of the randomized, double-blind, controlled trial of risperidone and haloperidol study for 12 week in autistic children and adolescents. A total of 28 subjects between 8 and 18 ages with autistic disorder were enrolled to the open label phase of the study. Behavioral rating scales (Clinical Global Impression Scale [CGI-I], Ritvo-Freeman Real Life Rating Scale [RF-RLRS]), Aberrant Behavior Checklist [ABC], Turgay DSM-IV Pervasive Developmental Disorder Rating Scale [TPDDRS]) and safety assessment scales (Extrapyramidal Symptoms Rating Scale [ESRS], UKU-Side Effect Rating Scale) were performed at 12, 16, 20 and 24 weeks, following the 12 week double-blind phase. Risperidone and haloperidol treatments were applied with a once daily dosage regimen as 0.01-0.08 mg/kg/day. RESULTS:Risperidone led to a significant greater reduction on CGI scale. There was significant improvement on RF-RLRS sensory motor and language subscale and ABC scores in risperidone group. Weight gain was observed more frequently in the haloperidol group at week 24. CONCLUSIONS: These results demonstrate that risperidone is more efficacious and well tolerated than haloperidol in the long-term maintenance treatment of autistic disorder.
RCT Entities:
BACKGROUND: The aim of the study was to investigate safety, efficacy and tolerability of risperidone in comparison with haloperidol in the long-term treatment of autistic disorder. METHODS: This was an open-label continuation study of the randomized, double-blind, controlled trial of risperidone and haloperidol study for 12 week in autisticchildren and adolescents. A total of 28 subjects between 8 and 18 ages with autistic disorder were enrolled to the open label phase of the study. Behavioral rating scales (Clinical Global Impression Scale [CGI-I], Ritvo-Freeman Real Life Rating Scale [RF-RLRS]), Aberrant Behavior Checklist [ABC], Turgay DSM-IV Pervasive Developmental Disorder Rating Scale [TPDDRS]) and safety assessment scales (Extrapyramidal Symptoms Rating Scale [ESRS], UKU-Side Effect Rating Scale) were performed at 12, 16, 20 and 24 weeks, following the 12 week double-blind phase. Risperidone and haloperidol treatments were applied with a once daily dosage regimen as 0.01-0.08 mg/kg/day. RESULTS:Risperidone led to a significant greater reduction on CGI scale. There was significant improvement on RF-RLRS sensory motor and language subscale and ABC scores in risperidone group. Weight gain was observed more frequently in the haloperidol group at week 24. CONCLUSIONS: These results demonstrate that risperidone is more efficacious and well tolerated than haloperidol in the long-term maintenance treatment of autistic disorder.
Authors: C J McDougle; J P Holmes; M R Bronson; G M Anderson; F R Volkmar; L H Price; D J Cohen Journal: J Am Acad Child Adolesc Psychiatry Date: 1997-05 Impact factor: 8.829
Authors: Andrés Martin; Lawrence Scahill; George M Anderson; Michael Aman; L Eugene Arnold; James McCracken; Christopher J McDougle; Elaine Tierney; Shirley Chuang; Benedetto Vitiello Journal: Am J Psychiatry Date: 2004-06 Impact factor: 18.112
Authors: E R Ritvo; B J Freeman; A Yuwiler; E Geller; P Schroth; A Yokota; A Mason-Brothers; G J August; W Klykylo; B Leventhal Journal: Psychopharmacol Bull Date: 1986
Authors: Richard P Malone; Greg Maislin; Muniya S Choudhury; Cynthia Gifford; Mary Anne Delaney Journal: J Am Acad Child Adolesc Psychiatry Date: 2002-02 Impact factor: 8.829
Authors: L Eugene Arnold; Benedetto Vitiello; Christopher McDougle; Larry Scahill; Bhavik Shah; Nilda M Gonzalez; Shirley Chuang; Mark Davies; Jill Hollway; Michael G Aman; Pegeen Cronin; Kathleen Koenig; Arlene E Kohn; Donald J McMahon; Elaine Tierney Journal: J Am Acad Child Adolesc Psychiatry Date: 2003-12 Impact factor: 8.829
Authors: José María Martínez-Ortega; Silvia Funes-Godoy; Francisco Díaz-Atienza; Luis Gutiérrez-Rojas; Lucía Pérez-Costillas; Manuel Gurpegui Journal: Eur Child Adolesc Psychiatry Date: 2013-03-17 Impact factor: 4.785